


**Product Name** : ON123300  
**Cat. No.** : PC-43121  
**CAS No.** : 1357470-29-1  
**Molecular Formula** : C<sub>24</sub>H<sub>27</sub>N<sub>7</sub>O  
**Molecular Weight** : 429.5175  
**Target** : Cyclin-dependent Kinase (CDK)  
**Solubility** : 10 mM in DMSO



## Biological Activity

Narazaciclib (ON123300) is a potent, **multi-targeted kinase** inhibitor with IC<sub>50</sub> of 5, 3.9, 26, 26, 9.2 and 11 nM for **ARK5**, CDK4, PDGFRβ, FGFR1, RET and FYN, respectively.

Narazaciclib (ON123300) inhibits U87 glioma cell proliferation with IC<sub>50</sub> 3.4 μM, and reduces phosphorylation of Akt, yet it also unexpectedly induces Erk activation and prevents phosphorylation of C-Raf S259.

Narazaciclib (ON123300) suppresses phosphorylation of Akt as well as activation of Erk in brain tumors in vivo.

Narazaciclib (ON123300) also exhibits potent activity against mantle cell lymphomas both in vitro and in vivo, triggers apoptosis and inhibition of the Rb and PI3K/AKT pathways.

## References

Zhang X, et al. *Mol Cancer Ther.* 2014 May;13(5):1105-16.

Divakar SK, et al. *Leukemia.* 2016 Jan;30(1):86-93.

Perumal D, et al. *Cancer Res.* 2016 Mar 1;76(5):1225-36.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com